Groundbreaking tests for sepsis and fever detection

The Inflammatix host response diagnostics are powered by ‘reading’ the immune system instead of looking for a bug. Our immune system has developed targeted responses to different types of infections and other diseases over millions of years of evolution.

We are initially launching InSep and ViraBac for better acute infection and sepsis diagnosis based on patent-pending biomarkers exclusively licensed from Stanford University.

All products are in development and are not FDA cleared.


Acute Infection and Sepsis Test

Shooting for the holy grail: Identify the presence, type and severity of an acute infection.

Tailored for emergency rooms, urgent care clinics and inpatient use to diagnose (or rule out) acute infection and sepsis in multiple clinical scenarios:

  • First presentation in the ED or urgent care clinic
  • Identifying infections in traumatic injuries
  • Neonate and ICU patient monitoring

The InSep test is in development, not FDA cleared.


Acute Infection Test

Soon, we’ll answer your simple question:
Is my infection bacterial or viral?

Ideal for outpatient clinics and urgent care centers. Safely and confidently avoid prescribing antibiotics on negative results (multiple validation studies indicate that the ViraBac test can achieve a greater than 95% negative predictive value for bacterial infection)


Discover our publications and abstracts


Our Approach

Our approach to developing host response-based diagnostic tests has yielded remarkable results to date

Focus on what clinicians want

Every test should be built with a physician end-user in mind. Our team is physician-led, ensuring that development starts with the question of whether a test could be clinically actionable, and whether it fits into workflow. Our test for sepsis was built to answer a critical clinical gap: physicians usually guess about whether or not a patient needs antibiotics. Current pathogen-focused diagnostic methods fail to answer this question because they frequently miss infections that haven’t spread to the bloodstream. Thus, we focused on using the immune response to infections to answer to key clinical action items in the evaluation of an acutely ill patient: (1) does the patient need antibiotics, and (2) what level of care is required? These questions are best answered by ‘reading’ the immune response, rather than looking directly for a pathogen as a ‘needle in a haystack’.

Embrace heterogenous data in product development

Embrace heterogenous data in selecting and analyzing cohorts to study. Acute infections can be remarkably clinically diverse: kids and adults, inpatients and outpatients, in different settings around the world. We wanted to build a test that would work in every environment. We thus embrace this clinical heterogeneity by analyzing multiple cohorts that are diverse in their population, sample types, assays used and other factors. Our robust statistical pipeline allows us to find reproducible signal in the ‘noise’ of multiple datasets. Although this is a hard challenge, our discovery methods ensure that the diagnostics we find are generalizable to new populations.

Validate externally

Validate on multiple, independent and diverse cohorts. Trustworthy tests must demonstrate robust performance in independent, blinded multi-center studies.

Deep Pipeline of Novel, Rapid Tests

InSep Barchart

Stay in touch with social updates:
Find out the latest news.

Follow us on Twitter
Follow us on LinkedIn